The Soluble CTLA-4 Splice Variant Protects from Type 1 Diabetes and Potentiates Regulatory T-cell Function

Overview

Journal Diabetes

Specialty Endocrinology

Date 2011 May 24

PMID 21602513

Citations 53

Authors

Kay D Gerold

Peilin Zheng

Daniel B Rainbow

Alma Zernecke

Linda S Wicker

Stephan Kissler

Affiliations

Soon will be listed here.

Abstract

Objective: CTLA4 gene variation associates with multiple autoimmune disorders, including type 1 diabetes. The CTLA4 susceptibility allele was found to generate decreased levels of mRNA encoding soluble CTLA-4 (sCTLA-4) relative to the full-length isoform, the functional consequence of which is as yet unknown. In this study, we investigated the contribution of sCTLA-4 to immune regulation with the aim to elucidate the functional basis of the disease association of CTLA4.

Research Design And Methods: To model the disease-associated splicing variation of CTLA4, we generated NOD mice in which sCTLA-4 mRNA is silenced by RNA interference.

Results: We found that loss of sCTLA-4 impairs the function of regulatory T (Treg) cells. This functional defect could be attributed, at least in part, to the failure of sCTLA-4 knockdown (KD) Treg cells to downregulate dendritic cell costimulation. sCTLA-4 KD Treg cells, in contrast with wild-type Treg cells, failed to inhibit colitis induced by transfer of CD4(+)CD45RB(hi) cells into NOD.SCID animals. Furthermore, diminished sCTLA-4 expression accelerated the onset of autoimmune diabetes in transgenic mice.

Conclusions: Our results demonstrate that sCTLA-4 participates in immune regulation by potentiating the function of Treg cells. The functional outcome of silencing this splice variant in the NOD model provides an explanation for the association of CTLA4 variation with autoimmunity. Lower sCTLA-4 expression from the susceptibility allele may directly affect the suppressive capacity of Treg cells and thereby modulate disease risk. Our unprecedented approach establishes the feasibility of modeling splicing variations relevant to autoimmunity.

Citing Articles

Risk Allele rs117026326-Mediated Alternative Splicing of GTF2I Promotes B Cell Proliferation in Primary Sjögren's Syndrome.

Luo C, Lian C, Sun J, Zhao L, Zhang S, Li Y J Immunol Res. 2025; 2025:4821639.

PMID: 40007754 PMC: 11858827. DOI: 10.1155/jimr/4821639.

Mini-Review: Tregs as a Tool for Therapy-Obvious and Non-Obvious Challenges and Solutions.

Morgun E, Govorova I, Chernysheva M, Machinskaya M, Vorotelyak E Cells. 2024; 13(20.

PMID: 39451198 PMC: 11506333. DOI: 10.3390/cells13201680.

Decoding the genetic influence of CT60 non-coding polymorphism in CTLA-4 gene and sCTLA-4 biomarker with rheumatoid arthritis in the Indian population.

Shamala V, Asha Devi S Mol Biol Rep. 2024; 51(1):1023.

PMID: 39340674 DOI: 10.1007/s11033-024-09949-w.

Evaluation of genetic association between celiac disease and type 1 diabetes.

Malekahmadi S, Asri N, Forouzesh F, Saneifard H, Rezaei-Tavirani M, Rostami-Nejad M J Diabetes Metab Disord. 2024; 23(1):1329-1336.

PMID: 38932832 PMC: 11196513. DOI: 10.1007/s40200-024-01429-z.

Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies.

Bauer M, Schobel C, Wickenhauser C, Seliger B, Jasinski-Bergner S Front Immunol. 2024; 15:1386993.

PMID: 38736877 PMC: 11082354. DOI: 10.3389/fimmu.2024.1386993.

References

Dendrou C, Plagnol V, Fung E, Yang J, Downes K, Cooper J . Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009; 41(9):1011-5. PMC: 2749506. DOI: 10.1038/ng.434. View

Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S . Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008; 105(29):10113-8. PMC: 2481354. DOI: 10.1073/pnas.0711106105. View

Ueda H, Howson J, Esposito L, Heward J, Snook H, Chamberlain G . Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003; 423(6939):506-11. DOI: 10.1038/nature01621. View

Oaks M, Hallett K, Penwell R, Stauber E, Warren S, Tector A . A native soluble form of CTLA-4. Cell Immunol. 2000; 201(2):144-53. DOI: 10.1006/cimm.2000.1649. View

Nistico L, Buzzetti R, Pritchard L, Van der Auwera B, Giovannini C, Bosi E . The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet. 1996; 5(7):1075-80. DOI: 10.1093/hmg/5.7.1075. View

Ostrov D, Shi W, Schwartz J, Almo S, Nathenson S . Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science. 2000; 290(5492):816-9. DOI: 10.1126/science.290.5492.816. View

Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner V . Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet. 2007; 39(3):329-37. PMC: 2886969. DOI: 10.1038/ng1958. View

Stegmeier F, Hu G, Rickles R, Hannon G, Elledge S . A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A. 2005; 102(37):13212-7. PMC: 1196357. DOI: 10.1073/pnas.0506306102. View

Wang E, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C . Alternative isoform regulation in human tissue transcriptomes. Nature. 2008; 456(7221):470-6. PMC: 2593745. DOI: 10.1038/nature07509. View

10.

Alyanakian M, You S, Damotte D, Gouarin C, Esling A, Garcia C . Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci U S A. 2003; 100(26):15806-11. PMC: 307649. DOI: 10.1073/pnas.2636971100. View

11.

Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N . Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198(12):1875-86. PMC: 2194145. DOI: 10.1084/jem.20030152. View

12.

Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L . Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol. 2006; 177(7):4376-83. PMC: 6108417. DOI: 10.4049/jimmunol.177.7.4376. View

13.

Fallarino F, Grohmann U, Hwang K, Orabona C, Vacca C, Bianchi R . Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003; 4(12):1206-12. DOI: 10.1038/ni1003. View

14.

Barrett J, Clayton D, Concannon P, Akolkar B, Cooper J, Erlich H . Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009; 41(6):703-7. PMC: 2889014. DOI: 10.1038/ng.381. View

15.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

16.

Wicker L, Chamberlain G, Hunter K, Rainbow D, Howlett S, Tiffen P . Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J Immunol. 2004; 173(1):164-73. DOI: 10.4049/jimmunol.173.1.164. View

17.

Cederbom L, Hall H, Ivars F . CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000; 30(6):1538-43. DOI: 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X. View

18.

Waterhouse P, Penninger J, Timms E, Wakeham A, Shahinian A, Lee K . Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995; 270(5238):985-8. DOI: 10.1126/science.270.5238.985. View

19.

Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z . CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008; 322(5899):271-5. DOI: 10.1126/science.1160062. View

20.

Atabani S, Thio C, Divanovic S, Trompette A, Belkaid Y, Thomas D . Association of CTLA4 polymorphism with regulatory T cell frequency. Eur J Immunol. 2005; 35(7):2157-62. DOI: 10.1002/eji.200526168. View